South America Epirubicin Market

The SAM epirubicin market is expected to grow from US$ 9,806.94 thousand in 2022 to US$ 11,560.12 thousand by 2028; it is estimated to grow at a CAGR of 2.8% from 2022 to 2028.       

Rising Number of Cancer Research Programs Boosts Epirubicin Market

Cancer is the one of the leading causes of mortality across the region. Furthermore, several researchers across the region are working on cancer research programs. Some research is fundamental, exploring questions as diverse as the biological foundations of cancer and the social factors that affect cancer risk. Several research efforts have taken place in recent years. For instance, the Breast Specialized Programs of Research Excellence (Breast SPOREs) are designed to move basic scientific findings into clinical settings quickly. The Breast SPOREs support the development of new therapies, technologies, and studies for a better understanding of tumor resistance, diagnosis, prognosis, screening, prevention, and treatment of breast cancer. Secondly, the Cancer Intervention and Surveillance Modeling Network (CISNET) focuses using modeling to improve knowledge to prevent, early detection, screening, and treatment affect breast cancer results. Ongoing programs help prevention and early detection research in different cancers. The factors mentioned above would fuel the growth of the epirubicin market across the region.    

Market Overview

The SAM epirubicin market is segmented into Brazil, Argentina, and the Rest of SAM. The market growth is attributed to an increase in the prevalence of cancer, a surge in various research activities, increasing awareness regarding diagnostic imaging procedures, and rising healthcare expenditure. As per the International Trade Administration (ITA), Brazil is the largest healthcare market in Latin America and spends 9.1% of its GDP on healthcare. For instance, health spending in Brazil is expected to increase from 9.6% of GDP in 2019 to 12.6% of GDP by 2040. The growth in healthcare spending results in providing better care for patients in the country by launching awareness programs for diseases, routine checkups for early disease diagnosis, and better treatment facilities, among others. Healthcare spending can be used to increase the efficiency of primary health care, hospital care, pharmaceuticals, long-term care, and governance. Thus, an increase in healthcare spending across the country is also expected to fuel the market growth during the forecast period.    

SAM Epirubicin Market Revenue and Forecast to 2028 (US$ Thousand)    

SAM Epirubicin Market Segmentation    

The SAM epirubicin market is segmented based on dosage, application, distribution channel, and country  

• Based on dosage, the SAM epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. The 50mg/vial segment held the largest market share in 2022. 
• Based on application, the SAM epirubicin market is segmented into breast cancer, liver cancer, bladder cancer, and others. The breast cancer segment held the largest market share in 2022.
• Based on distribution channel, the SAM epirubicin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2022.   
• Based on country, the SAM epirubicin market is segmented into Brazil, Argentina, and the Rest of SAM. Further, Brazil dominated the market in 2022.        

Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., and Teva Pharmaceutical Industries Ltd. are the leading companies operating in the SAM epirubicin market.

South America Epirubicin Market Strategic Insights

South America Epirubicin Market Segmentation Analysis

South America Epirubicin Market Report Highlights

South America Epirubicin Report Scope

South America Epirubicin Market Country and Regional Insights